Clinical Trial

Effect of vitamin B_{12} supplementation on glycemic control in poorly controlled hyperhomocysteinemic type 2 diabetic patients

Yogendra Narayanrao Keche[1], Radha Yegnanarayan[2] and Shreepad Bhat[3]

[1]C.M. Medical College and Hospital, Kachandur, Durg 490 024, India; [2]Smt Kashibai Navale Medical College and General Hospital, Narhe Ambegaon, Pune, Maharashtra 411 041, India; [3]Smt Kashibai Navale Medical College and General Hospital, Narhe Ambegaon, Pune, Maharashtra 411 041, India.

Article Info

Abstract

This study was conducted to observe the effect of vitamin B_{12} supplementation on glycemic control in poorly controlled hyperhomocysteinemic type 2 diabetic patients by measuring HbA1c levels at baseline and 4 weeks. Patient having serum homocysteine more than 15 µmol/L or vitamin B_{12} less than 223 pg/mL were enrolled in this study. One group received methylcobalamin 500 µg daily with their usual anti-diabetic therapy and the other group received only suitable anti-diabetic drug therapy. Methylcobalamin 500 µg was given daily for period of 4 weeks. Glycemic control was measured by levels of HbA1c, blood sugar at baseline and at 4 weeks. Serum homocysteine levels was reduced from 21.5 ± 2.6 to 15.4 ± 6.4 (p=0.04) with vitamin B_{12} supplementation at 4 weeks. At 4 weeks, HbA1c decreased from 9.9 ± 0.9 to 8.7 ± 0.5 (p<0.01) in vitamin B_{12} deficient patients after vitamin B_{12} supplementation. There is role of vitamin B_{12} in glycemic control in poorly controlled type 2 diabetic patients.

Introduction

Hyperhomocysteinemia is observed in type 2 diabetes and it is associated with macroangiopathy, nephropathy and microalbuminuria (Buysschaert et al., 2000; Jager et al., 2001). Hyperhomocysteinemia is a risk factor for atherosclerosis (Mahendran et al., 2013). Moderately raised plasma homocysteine was obtained with associated decreased folic acid and vitamin B_{12} levels in type 2 diabetes subjects (Soinio 2004; Klee 2000; Ebesunun and Obajobi, 2012). Raised homocysteine levels are associated with raised levels of bad cholesterol and decreased levels of good cholesterol (Mahendran et al., 2013; Ramachandran et al., 2012).

Homocysteine is independently associated with the prevalence of diabetic neuropathy in type 2 diabetic patients (Ambrosch 2001). Metformin also causes vitamin B_{12} deficiency. There is no evidence that patholo-

gical levels of the biochemical markers of B_{12} are more common in metformin-treated compared with non–metformin-treated patients, despite lowering B_{12} in serum or plasma (Obeid, 2014).

Vitamin B_{12} 100 µg alternate day with low fat vegan diet resulted in improvement in glycemic and lipid control (Barnard et al., 2006) Therapy with folic acid, vitamin B_{12}, and vitamin B_6 significantly decreases the incidence of major adverse events after percutaneous coronary intervention (Schnyder 2002). This study was planned to study effect of vitamin B_{12} supplementation on glycemic control in poorly controlled hyperhomocysteinemic type 2 diabetic patients with objectives: a) glycemic control measured by levels of glycosylated hemoglobin (HbA1c) at baseline and 4 weeks; b) fasting blood sugar level at baseline and 4 weeks; c) serum homocysteine/vitamin B_{12} levels at baseline and 4 weeks; d) serum lipid profile at baseline and 4 weeks.

Materials and Methods

Patients not responding adequately to oral anti-diabetic agents were recruited from Medicine OPD with the help of treating physician. Patient were first screened for serum homocysteine/vitamin B_{12} level along with all baseline investigations. Those having serum homocysteine level more than 15 µmol/L or vitamin B_{12} level less than 223 pg/mL were enrolled in this study. Due to high cost for investigation, serum homocysteine level was measured only in 6 patients and serum vitamin B_{12} level was measured in 14 patients with prior permission from Ethics Committee.

Inclusion criteria for this study were: Age between 30 - 70 years, male, non-lactating female, HbA1 >8%, serum homocysteine >15 µmol/L or serum vitamin B_{12} level <223 pg/mL ischemic heart disease (IHD) or non-IHD patients. Exclusion criteria were: Age <30 years, pregnancy, lactating mother, patient with insulin dependent diabetes mellitus, severe and complicated diabetes, patients with hepatic or renal dysfunction. After enrolment of patients for the study, all the baseline investigations were carried out at Central Clinical Laboratory except Hb1Ac which was carried out at Department of Pharmacology. Serum homocysteine or vitamin B_{12} estimation was carried out in an accredited laboratory. There were two groups of poorly controlled patient; Drug group received methylcobalamin 500 µg daily with their usual anti-diabetic therapy and the control group received suitable anti-diabetic drug therapy as prescribed by treating physician. Methylcobalamin 500 µg was given once daily for the period of 4 weeks and were followed-up at 4 weeks. At baseline all the investigations were carried out (Figure 1).

Reporting of adverse effects

All patients were given checklist of adverse effects of vitamin B_{12} and information about adverse drug reactions was collected in follow-up. Patients unable tolerate adverse drug reactions, were advised to contact any of investigators at any time for review and advice.

Sample size calculation and statistical analysis

Sample size of 20 for each group was calculated in the ratio of 1, power 80%, considering 10-fold difference of drug effect in vitamin B12 group and control group by using Open Epi 2.3 (2009). Randomization was done with the help of randomization software (Rando 1.2, 2004). Statistical analysis was done by using Open Epi 2.3, 2009) and Microsoft Excel.

Results

In this study, 20 patients completed study in drug group and 18 patients in control group. There was no significant difference in demography in both the groups. There was no significant difference in baseline parameters (Table I)

There was significant fall in serum homocysteine levels with vitamin B_{12} supplementation in hyperhomocystenemic type 2 diabetic patients at 4 weeks. No significant fall in blood sugar levels and HbA1c levels was observed after vitamin B_{12} supplementation in hyperhomocystenemic type 2 diabetic patients at 4 weeks. No significant beneficial effect was observed on lipid profile at 4 weeks after vitamin B_{12} supplementation (Table II).

There was significant rise in vitamin B_{12} levels and significant fall in HbA1c levels in vitamin B_{12} deficient patients with vitamin B_{12} supplementation at 4 weeks (Table III).

Combined data of poorly controlled hyperhomo-

Baseline

Control group
Body weight, height, blood pressure, HbA1c level, blood sugar-fasting/postprandial, serum lipid profile (to measure the effect of vitamin B_{12}), blood urea, serum creatinine, serum bilirubin, SGOT, SGPT, alkaline phosphatase (to rule out hepatic or renal dysfunction), routine urine examination for albumin ECG (to rule out cardiac abnormality viz, IHD, arrhythmias); serum vitamin B_{12} (n = 18)

Drug group
Body weight, height, blood pressure, HbA1c level, blood sugar-fasting/postprandial, serum lipid profile (to measure the effect of vitamin B_{12}), blood urea, serum creatinine, serum bilirubin, SGOT, SGPT, alkaline phosphatase (to rule out hepatic or renal dysfunction), routine urine examination for albumin ECG (to rule out cardiac abnormality viz, IHD, arrhythmias); serum vitamin B_{12} (n = 14); serum homocysteine (n = 6)

After 4 Weeks

Control group
Body weight, blood pressure, HbA1c level, blood sugar-fasting/PP, serum lipid profile urine albumin

Drug group
Repeat all investigations as baseline

Figure 1: Flow chart of investigations

Table I		
Demographic characteristics		
Parameter	Drug group (n=20)	Control group (n=18)
Sex		
Male	3 (15%)	4 (22.2%)
Female	17 (85%)	14 (77.7%)
Age (years)	51.8 ± 8.9	55.1 ± 7.9
Weight (kg)	61.0 ± 5.9	60.8 ± 11.9
HbA1c (%)	10.0 ± 0.8	9.3 ± 1.0
Fasting blood sugar level (mg/dL)	157.6 ± 61.3	132.1 ± 29.7
Postprandial blood sugar level (mg/dL)	239.2 ± 111.2	208.7 ± 62.3

Data are mean ± SD

cystenemic and vitamin B12 deficient type 2 diabetic patients had shown significant fall in HbA1c levels at 4 weeks (Table IV).

Discussion

In this study, a dose 500 µg/day was used orally for 4 weeks in poorly controlled type 2 diabetic patients with either hyperhomocysteinemia or vitamin B_{12} deficiency. There was significant decrease in levels of homocysteine from 21.5 ± 2.6 to 15.4 ± 6.4, (p=0.04) with vitamin B_{12} supplementation for four weeks. In vitamin B_{12} deficient and hyperhomocystenemic type 2 diabetic patients, there was significant decrease in HbA1c levels from 9.9 ± 0.9 to 8.7 ± 0.5, (p<0.01) with vitamin B_{12} supplementation for 4 weeks. This study has proved that vitamin B_{12} alone can also reduce homocysteine level in hyperhomocystenemic type 2 diabetic patients.

In adult patients with type 2 diabetes, intra muscular or oral vitamin B_{12} in doses of 1000 µg daily for a week then once every week for 4 weeks are sufficient to correct vitamin B_{12} deficiency (Kibirige and Mwebaze, 2013). Vitamin B_{12} 100 µg alternate day with low fat vegan diet resulted in improvement in glycemic and lipid control (Barnard et al., 2006). Therapy with folic acid, vitamin B_{12}, and vitamin B_6 significantly decreases the incidence of major adverse events after percutaneous coronary intervention (Schnyder et al., 2002). Vitamin B_{12} replacement has been shown to cause symptomatic improvement among patients with severe diabetic neuropathy (Kibirige and Mwebaze, 2013; Talaei et al., 2009).

As higher homocysteine level in poorly controlled type 2 diabetic patient is associated with poor glycemic control (raised HbA1c) and micro-macro vascular complication (Ramachandran et al., 2012), correction of homocysteine level and correction of vitamin B_{12} deficiency which is one of the factor raised homocysteine level would have resulted in beneficial improve-

Table II			
Vitamin B_{12} supplementation on glycemic control and lipid profile in hyperhomocystenemic poorly controlled type 2 diabetic patients			
Parameter	Baseline	After 4 weeks	p value
Serum homocysteine (µmol/L)	21.5 ± 2.6	15.4 ± 6.4	0.04
HbA1c (%)	10.0 ± 0.6	9.8 ± 0.8	0.57
Fasting blood sugar level (mg/dL)	181.5 ± 99.8	152.5 ± 65.1	0.57
Postprandial blood sugar level (mg/dL)	300.3 ± 193.8	260.6 ± 146.7	0.69
HDL (mg/dL)	41.9 ± 12.5	44.2 ± 12.1	0.75
Total cholesterol (mg/dL)	159.3 ± 25.4	156.8 ± 36.5	0.89
Triglycerides (mg/dL)	108.1 ± 32.5	105.9 ± 41.6	0.92

Data are mean ± SD

Table III			
Vitamin B_{12} supplementation on glycemic control in vitamin B_{12} deficient poorly controlled type 2 diabetis			
Parameter	Baseline	After 4 weeks	p value
Serum vitamin B_{12} (pg/mL)	203.8 ± 17.6	515.1 ± 77.4	<0.01
HbA1c (%)	9.9 ± 0.9	8.7 ± 0.5	<0.01
Fasting blood sugar level (mg/dL)	147.3 ± 35.9	130.3 ± 32.6	0.21
Postprandial blood sugar level (mg/dL)	213.0 ± 34.4	196.2 ± 59.7	0.37

Data are mean ± SD

Table IV					
Effect of vitamin B12 supplementation on glycemic control in poorly controlled type 2 diabetic patients					
	HbA1c (%)		Fasting blood sugar level (mg/dL)		Postprandial blood sugar level (mg/dL)	
	Baseline	4 weeks	Baseline	4 weeks	Baseline	4 weeks
Drug group (n=20)	10.0 ± 0.8	9.0 ± 0.8^a	157.6 ± 61.3	137.3 ± 44.7	239.2 ± 111.2	216.5 ± 96.4
Control group (n=18)	9.3 ± 1.0	9.2 ± 0.8	132.1 ± 29.7	140.6 ± 42.3	208.7 ± 62.3	222.1 ± 61.2
P value (compared with control)	0.02	0.43	0.11	0.81	0.29	0.83

[a]$p<0.001$ (paired t test as compared to baseline values)

ment in HbA1c in this study. For confirmation of the role of vitamin B_{12} in glycemic control vitamin B_{12} deficient patients further studies are needed in poorly controlled type 2 diabetic patients.

Conclusion

Homocysteine level reduced significantly after vitamin B_{12} supplementation for 4 weeks in hyperhomocysteinemic poorly controlled type 2 diabetic patients. In vitamin B_{12} deficient, there was significant fall in HbA1c levels after vitamin B_{12} supplementation for 4 weeks. There is role of vitamin B_{12} in glycaemic control in type 2 diabetic patients.

Ethical Issue

The study protocol was approved by the local Institutional Ethics Committee. Patients were given all the information about vitamin B_{12} (methylcobalamin) including adverse effects. A written informed consent was taken from each patient and those who were willing to participate in study were enrolled in this study. All the information was recorded in case report forms. The study was registered in clinicaltrials.gov (NCT02540642).

References

Ambrosch A. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabetic Med. 2001; 18: 185-92.

Buysschaert M, Dramais A-S, Wallemacq PE, Hermans MP: Hyperhomocysteinemia in type 2 diabetes: Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care. 2000; 23: 1816–22.

Barnard ND, Cohen J, Jenkins DJ, Turner-Mc Grievy G, Gloede L, Jaster B, Seidl K, Green AA, Talpers S. A low fat vegan diet improves glycaemic control and cardiovascular risk factors in randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006; 29: 1777-83.

Ebesunun MO, Obajobi EO. Elevated plasma homocysteine in type 2 diabetes mellitus: A risk factor for cardiovascular diseases. Pan African Med J. 2012; 12: 48.

Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Donker AJM, Stehouwer CD. Serum homocysteine levels are associated with the development of (micro) albuminuria: The Hoorn Study. Arterioscler Thromb Vasc Biol. 2001; 21: 74-81.

Kibirige D, Mwebaze R. Vitamin B_{12} deficiency among patients with diabetes mellitus: Is routine screening and supplementation justified? J Diabetes Metabol Dis. 2013; 12: 17.

Klee GG. Cobalamin and folate evaluation: Measurement of methylmalonic acid and homocysteine vs vitamin B_{12} and folate. Clin Chem. 2000; 46: 1277-83.

Mahendran KB, Santha K, Santhoshkumar N, Desigan EG, Mohammad A. Serum homocysteine and lipid profile levels in type 2 diabetes mellitus patients. Int J Med Res Health Sci. 2013; 2: 200-05.

Obeid R. Metformin causing vitamin B_{12} deficiency: A guilty verdict without sufficient evidence. Diabetes Care. 2014; 37: e22–23.

Ramachandran L, Negi NS, Gupta B. Prevalence of hyperhomocysteinaemia in type 2 diabetes mellitus and its correlation with its complications. J Ind Aca Clin Med. 2012; 13: 277-81.

Schnyder G. Effect of homocysteine-lowering therapy with folic acid, vitamin B_{12}, and vitamin B_6 on clinical outcome after Percutaneous Coronary Intervention The Swiss Heart Study: A randomized controlled trial. JAMA. 2002; 288: 973-79.

Soinio M. High Homocysteine levels increase risk for heart attacks in people with type 2 diabetes mellitus. Ann Intern Med. 2004; 140: 1-31.

Talaei A, Siavash M, Majidi H, Chehrei A. Vitamin B_{12} may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr. 2009; 60: 71–76.

Author Info
Yogendra Narayanrao Keche (Principal contact)
e-mail: drynkeche@gmail.com; Mobile: +918818882119

Your feedback about this paper

1. Number of times you have read this paper

2. Quality of paper

      Excellent   Good   Moderate   Not good

3. Your comments